Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020917 · ClinicalTrials.gov registry record · Phase 2
Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00020917: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00020917 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020917, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cetuximab with combination chemotherapy in treating patients who have stage IV colorectal cancer.
Interventions
- DRUG fluorouracil
- BIOLOGICAL cetuximab
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-02 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
What the finished NCT00020917 record still lists
NCT00020917 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which fluorouracil is the first listed.
NCT00020917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00020917 about?
NCT00020917 is a clinical study titled "Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer". RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal a...
What is the current status of trial NCT00020917?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-02. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00020917?
The interventions under investigation include: fluorouracil (DRUG), cetuximab (BIOLOGICAL), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00020917?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia